Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618001073291
Ethics application status
Approved
Date submitted
1/12/2017
Date registered
27/06/2018
Date last updated
22/06/2022
Date data sharing statement initially provided
22/06/2022
Date results provided
22/06/2022
Type of registration
Retrospectively registered

Titles & IDs
Public title
An early phase clinical trial evaluating the effectiveness of treatment of 177Lu-PSMA with idronoxil in men with castrate-resistant prostate cancer (LuPin Trial)
Scientific title
Radionuclide therapy using 177Lu-PSMA: extension of a pilot study in men with castrate-resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil
Secondary ID [1] 293512 0
Nil Known
Universal Trial Number (UTN)
U1111-1206-1132
Trial acronym
LuPin
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Castrate-resistant prostate cancer 305696 0
Condition category
Condition code
Cancer 304916 304916 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This an open label non-randomised phase I/II study in men with prostate specific membrane antigen (PSMA) positive, hormone refractory, progressive prostate cancer present within the preceding 6 months based on radiology and or symptomatic progression.

There are three cohorts which will receive up to six cycles of therapeutic 177 Lu-PSMA combined with either idronoxil 400 mg daily, idronoxil 800 mg daily or idronoxil 1200 mg daily depending on patient response. Enrolment into the higher dose level of idronoxil will only occur after prior cohort is filled and data safety monitoring recommendation to proceed. Each cohort will undergo a 42 day treatment cycle with a single IV injection of 177 Lu-PSMA on day 0 of each cycle. The dose given is calculated by the doctor based on the participant's weight and volume of disease. Dose will vary between individuals. Both cohorts, following administration of 177 Lu-PSMA, will provided with the appropriate idronoxil to self administer at home once a day for the following 9 days. Idronoxil are suppositories and participants will be instructed on the method of administration and provided with instruction sheet.

Participants will routinely follow up with treating doctor before each cycle to assess benefit of treatment and adherence to study. Each 42 day cycle will follow the same plan and the participant will continue onto next cycle with .
Intervention code [1] 299744 0
Treatment: Drugs
Intervention code [2] 299875 0
Treatment: Other
Comparator / control treatment
The 400 mg daily cohort, the 800 mg daily cohort and the 1200 mg daily cohort will be compared to each other
Control group
Dose comparison

Outcomes
Primary outcome [1] 304109 0
To determine the toxicity profile of combination therapy of idronoxil and 177Lu PSMA graded by CTCAE version 4.03
Timepoint [1] 304109 0
The assessments will occur at baseline, after one cycle of treatment and at the end of each cycle thereafter.
Primary outcome [2] 304257 0
To document the anti-cancer efficacy using 177Lu-PSMA-idronoxil combination therapy using a composite of surrogate measures including serum PSA, medical imaging, EORTC QLQ-C30 and BPI-SF.
Timepoint [2] 304257 0
The assessments will occur at baseline, after one cycle of treatment and at the end of each cycle thereafter.

The efficacy will be determined by
a. QOL scores (EORTC QLQ-C30)
b. Pain scores (BPI-SF)
c. Radiologic response 3 months post completion of therapy (RECIST v1.1): complete response, partial response, stable disease, progressive disease
d. Molecular imaging response post dose 2 and 3 months post completion of therapy: complete metabolic response, partial metabolic response, stable metabolic disease, progressive metabolic disease.
e. Serum PSA response 3 months post completion of therapy.
Secondary outcome [1] 341008 0
To investigate the normal tissue bio-distribution of repeated doses of 177Lu PSMA-idronoxil combination therapy using medical imaging tools (Isotope bone scan, Contrast enhanced CT, PSMA PET/CT, FDP PET/CT and 177Lu PSMA Q-SPECT imaging).
Timepoint [1] 341008 0
The assessments will occur at baseline, after one cycle of treatment and at the end of each cycle thereafter. Normal tissue dosimetry expressed in Gy.
Secondary outcome [2] 341376 0
To document the progression-free rates following combination therapy.
Timepoint [2] 341376 0
Progression-free rates are determined from date of commencement of PSMA therapy to documents progression. A participant will be followed up indefinitely or until the participant asks to be withdrawn from the study
Secondary outcome [3] 341377 0
To document changes in serum PSMA during therapy
Timepoint [3] 341377 0
Serum PSMA response 3 months following completion of therapy will be compared to the assessment at pre-treatment and during treatment (taken at the start of each cycle, day 14 and day 28 of each cycle).
Secondary outcome [4] 341378 0
An exploratory outcome to potentially identify biomarkers that are prognostic and/or predictive of response to treatment, safety and resistance to study treatment using serum assays.

Timepoint [4] 341378 0
Serum biomarkers of idronoxil function and response rate will be compared at baseline and post-treatment
Secondary outcome [5] 348055 0
To document the overall survival following combination therapy.
Timepoint [5] 348055 0
Progression-free rates are determined from date of commencement of PSMA therapy to documents progression. A participant will be followed up indefinitely or until the participant asks to be withdrawn from the study
Secondary outcome [6] 348056 0
To investigate the tumour localisation following repeated doses of 177Lu PSMA-idronoxil combination therapy using medical imaging tools (Isotope bone scan, Contrast enhanced CT, PSMA PET/CT, FDP PET/CT and 177Lu PSMA Q-SPECT imaging).
Timepoint [6] 348056 0
The assessments will occur at baseline, after one cycle of treatment and at the end of each cycle thereafter.
Secondary outcome [7] 348057 0
To investigate radiation dosimetry of repeated doses of 177Lu PSMA-idronoxil combination therapy using medical imaging tools (Isotope bone scan, Contrast enhanced CT, PSMA PET/CT, FDP PET/CT and 177Lu PSMA Q-SPECT imaging).
Timepoint [7] 348057 0
The assessments will occur at baseline, after one cycle of treatment and at the end of each cycle thereafter. Tumour dosimetry expressed in Gy.

Eligibility
Key inclusion criteria
1. Pathologically confirmed prostate adenocarcinoma
2. Castration-resistant metastatic disease, including prior treatment with Abiraterone, Enzalutamide or both (unless contraindicated, medically unsuitable or patient refuses)
3. Prior Taxane-based chemotherapy (unless contraindicated, medically unsuitable or patient refuses)
4. Objective evidence of disease progression within 6 months of study entry as defined by either:
a. Radiologic progression (RECIST v1.1 criteria) on conventional imaging
b. Symptoms refractory to standard medical care
5. PSMA PET/CT demonstrating uptake intensity significantly greater than liver at sites of disease
6. Written informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
1. Estimated GFR < 40 ml/min
2. Platelet count <100, 000 x109 /L
3. Neutrophil count < 1.5 x109 /L
4. Hb < 10.0 g/dL
5. Albumin less than or equal to 25
6. Hydronephrosis (untreated)
7. Concomitant nephrotoxic drugs (e.g. aminoglycosides)
8. ECOG performance status > 3
9. Life expectancy of less than 12 weeks
10. Age <18 years
11. FDG PET/CT demonstrating sites of major discordant disease (i.e. FDG + PSMA-)
12. Recent radiotherapy (within 6 weeks) to sole sites of assessable disease
13. Uncontrolled intercurrent illness that would limit compliance with study protocols
14. Unable to comply with study protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not applicable
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Primary end-points:
1. Descriptive statistics will be used to document change in pain scores, QOL scores, PSA response and imaging disease response at 3 months following completion of therapy compared to baseline scores along with 95% confidence interval.
a. For PSA, the percentage of patients with 50% decline from baseline will be described as per Prostate Cancer Working Group (PCWG2)24
2. The proportion of patients who suffer grade 1,2 3 or 4 toxicity will be provided along with its 95% confidence interval.

¬¬Secondary end-points:
1. Mean absorbed dose (Gy) estimated in in normal tissues and tumour will be recorded along with 95% confidence interval.
2. Kaplan-Meier methods will be used to describe progression free and overall survival at 6 and 12 months, defined from the date of start of treatment. This will be estimated from the Kaplan-Meier curve along with the corresponding 95% confidence intervals.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
4/12/2017
Date of last participant enrolment
Anticipated
Actual
6/02/2020
Date of last data collection
Anticipated
Actual
13/05/2022
Sample size
Target
56
Accrual to date
Final
56
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 9476 0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Recruitment postcode(s) [1] 18209 0
2010 - Darlinghurst

Funding & Sponsors
Funding source category [1] 298129 0
Commercial sector/Industry
Name [1] 298129 0
Noxopharm Limited
Country [1] 298129 0
Australia
Primary sponsor type
Hospital
Name
St Vincent's Hospital Sydney
Address
360 Victoria St
Darlinghurst NSW 2010
Country
Australia
Secondary sponsor category [1] 297209 0
None
Name [1] 297209 0
Address [1] 297209 0
Country [1] 297209 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 299148 0
St Vincent's Hospital HREC
Ethics committee address [1] 299148 0
Ethics committee country [1] 299148 0
Australia
Date submitted for ethics approval [1] 299148 0
30/01/2017
Approval date [1] 299148 0
13/10/2017
Ethics approval number [1] 299148 0
HREC/17/SVH/19

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 79458 0
A/Prof Louise Emmett
Address 79458 0
St Vincent’s Hospital Sydney
Nuclear Medicine and PET department
360 Victoria Street
Darlinghurst NSW 2010
Country 79458 0
Australia
Phone 79458 0
+612 8382 1824
Fax 79458 0
Email 79458 0
[email protected]
Contact person for public queries
Name 79459 0
Louise Emmett
Address 79459 0
St Vincent’s Hospital Sydney
Nuclear Medicine and PET department
360 Victoria Street
Darlinghurst NSW 2010
Country 79459 0
Australia
Phone 79459 0
+612 8382 1824
Fax 79459 0
Email 79459 0
[email protected]
Contact person for scientific queries
Name 79460 0
Louise Emmett
Address 79460 0
St Vincent’s Hospital Sydney
Nuclear Medicine and PET department
360 Victoria Street
Darlinghurst NSW 2010
Country 79460 0
Australia
Phone 79460 0
+612 8382 1824
Fax 79460 0
Email 79460 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Not ethics approved


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbasePhase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).2021https://dx.doi.org/10.1016/j.euo.2020.07.002
EmbaseThe Role of Theranostics in Prostate Cancer.2021https://dx.doi.org/10.1016/j.semradonc.2020.07.004
Embase177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial.2022https://dx.doi.org/10.2967/jnumed.121.262552
Dimensions AILutetium Lu 177 Vipivotide Tetraxetan: First Approval2022https://doi.org/10.1007/s40291-022-00594-2
EmbaseCirculating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617.2023https://dx.doi.org/10.1016/j.euros.2023.08.007
EmbaseEvaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).2023https://dx.doi.org/10.2967/jnumed.122.264398
EmbaseThe Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).2023https://dx.doi.org/10.2967/jnumed.122.264104
N.B. These documents automatically identified may not have been verified by the study sponsor.